Peanut protein

BIOLOGICAL4 trials

Sponsors

Hamilton Health Sciences Corporation, University of North Carolina, Chapel Hill, Scott Sicherer, Texas A&M University

Conditions

Food AllergyPeanut AllergyPeanut HypersensitivityProtein Metabolism

Early Phase 1

Oral Peanut Immunotherapy for Peanut Allergic Patients

CompletedNCT01891136

University of North Carolina, Chapel HillPeanut Hypersensitivity

Start: 2004-04-30End: 2014-12-31Updated: 2015-06-25

Phase 2

Peanut Allergy Oral Immunotherapy Desensitization

CompletedNCT01601522

Hamilton Health Sciences CorporationPeanut Allergy

Start: 2012-02-29End: 2021-09-30Updated: 2022-02-02

Immune Basis and Clinical Implications of Threshold-based Phenotypes of Peanut Allergy

CompletedNCT03907397

Scott SichererFood Allergy, Peanut Allergy

Start: 2019-08-05End: 2023-11-17Updated: 2025-02-07

Unknown Phase

Peanut Sip Feeding Protocol

Enrolling by invitationNCT06693544

Texas A&M UniversityProtein Metabolism

Start: 2024-10-23End: 2026-07-31Target: 15Updated: 2025-11-21

Related Papers

Coordinated changes in oral propionate, oral microbiota, and peripheral blood inflammatory processes during peanut oral immunotherapy.

2026-09-02

Peanut Oral Immunotherapy in Children with High-Threshold Peanut Allergy

NEJM Evidence2025-02-1013 citations

Tolerance induction through non-avoidance to prevent persistent food allergy (TINA) in children and adults with peanut or tree nut allergy: rationale, study design and methods of a randomized controlled trial and observational cohort study

Trials2022-03-2811 citations